Blackstone Inc Lumos Pharma, Inc. Transaction History

Blackstone Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.64 - $3.22 $654,529 - $798,328	-247,928 Reduced 75.92%	78,624 $221,000
Q4 2023 Feb 14, 2024	SELL	$2.81 - $4.27 $397,876 - $604,602	-141,593 Reduced 30.25%	326,552 $1.04 Million
Q1 2020 May 15, 2020	BUY	$0.89 - $8.85 $416,649 - $4.14 Million	468,145 New	468,145 $3.98 Million

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Blackstone Inc, based on Form 13F filings with the SEC.

Stay updated on Blackstone Inc with notifications on news.